A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Human psychopharmacology

• Publication date

  2002-01-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1002/hup.320PMID 12404702
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers

  2000cited by this paper
• Effects of 50mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep‐deprived subjects

  1999cited by this paper
• Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic.

  1999cited by this paper
• Lack of interaction between amisulpride and lorazepam on psychomotor performance and memory in healthy volunteers

  1998cited by this paper
• Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.

  1997cited by this paper
• The effects of haloperidol on visual search, eye movements and psychomotor performance

  1997cited by this paper
• Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers

  1997cited by this paper
• Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.

  1997cited by this paper
• Guidelines for the Use of Antipsychotic Drug Studies in Healthy Volunteers

  1997cited by this paper
• A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Schizophrenia

  1996cited by this paper
• Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects

  1996cited by this paper
• Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies.

  1996cited by this paper
• Side effect profiles of new antipsychotic agents.

  1996cited by this paper
• Remoxipride versus haloperidol in healthy volunteers: psychometric performance and subjective tolerance profiles

  1995cited by this paper
• Antipsychotic Drug-Induced Dysphoria

  1995cited by this paper
• Psychomotor impairment and cognitive disturbances induced by neuroleptics

  1994cited by this paper
• Subjective effects of neuroleptics predict compliance

  1994cited by this paper
• Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine.

  1994cited by this paper
• A comparison of the psychometric effects of remoxipride with those of haloperidol, thioridazine, and lorazepam in healthy volunteers

  1994cited by this paper
• Effects of granisetron and haloperidol, alone and in combination, on psychometric performance and the EEG.

  1992cited by this paper
• Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.

  1992cited by this paper
• Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.

  1991cited by this paper
• The Effect of Neuroleptics on Cognitive and Psychomotor Function

  1990cited by this paper
• A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers.

  1990cited by this paper
• A controlled dose comparison of haloperidol in newly admitted schizophrenic patients.

  1990cited by this paper
• The effects of neuroleptics on neuropsychological test results of schizophrenics.

  1988cited by this paper
• Positive and negative symptoms in schizophrenia.

  1984cited by this paper
• Determination of pharmacodynamics of the new neuroleptic zetidoline by neuroendocrinologic, pharmaco-EEG, and psychometric studies--Part I.

  1983cited by this paper
• Development of Scales Based on Patterns of Drug Effects, Using the Addiction Research Center Inventory (ARCI)

  1966cited by this paper

• Dose-dependent pharmacological mechanisms within the Neuroscience-based Nomenclature: a new concept to facilitate neuroscience-based prescribing.

  2026cites this paper
• Box-Behnken optimized salting-out assisted liquid-liquid extraction coupled with LC-MS/MS for sustainable amisulpride quantification in human plasma.

  2026cites this paper
• Utilizing Physiologically Based Pharmacokinetic Models to Support Rational Medication in Chinese Elderly Population

  2025cites this paper
• Olanzapine-Induced Ankle Edema: A Case Report on a Rare Adverse Effect

  2025cites this paper
• Amisulpride from the standpoint of efficacy and safety

  2025cites this paper
• Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting

  2024cites this paper
• Living systematic review and meta-analysis of plasma-concentrations of antipsychotic drugs in carriers and non-carriers of variant CYP450 genotypes: Living systematic review protocol

  2024cites this paper
• Pharmaceutical and Recreational Drug Usage Patterns during and Post COVID-19 Determined by Wastewater-Based Epidemiology

  2024cites this paper
• Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics

  2024cites this paper
• External Validation of the Population Pharmacokinetic Models of Amisulpride and Remedial Strategies for Delayed or Missed Doses

  2024cites this paper
• Perioperative utility of amisulpride and dopamine receptor antagonist antiemetics-a narrative review

  2023cites this paper
• Effects of a single dose of amisulpride on functional brain changes during reward- and motivation-related processing using task-based fMRI in healthy subjects and patients with major depressive disorder — study protocol for a randomized clinical trial

  2023cites this paper
• Does partial blockade of dopamine D2 receptors with Amisulpride cause anhedonia? An experimental study in healthy volunteers.

  2023cites this paper
• Limited Predictive Performance of Existing Amisulpride PopPK Models: External Validation and Proposal of Model-Based Remedial Regimens for Non-Adherence

  2023cites this paper
• Modeling the Double Peak Phenomenon in Drug Absorption Kinetics: The Case of Amisulpride

  2023cites this paper
• G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders

  2023cites this paper
• Effects of dopamine and opioid receptor antagonism on the neural processing of social and nonsocial rewards

  2023cites this paper
• Facial mimicry is not modulated by dopamine D2/3 and opioid receptor antagonism

  2023cites this paper
• Evaluation of the Role of Preoperative Oral Amisulpride as Part of a Multimodal Antiemetic Prophylaxis Regime on Postoperative Nausea and Vomiting in Patients Undergoing Craniotomy: A Prospective, Double-Blind, Randomized, Placebo-controlled Study

  2023cites this paper
• Population pharmacokinetics of Amisulpride in Chinese patients with schizophrenia with external validation: the impact of renal function

  2023cites this paper
• A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia

  2023influential citation
• Drug-Associated Liver Injury Related to Antipsychotics

  2022cites this paper
• Systematische Übersichtsarbeit Antipsychotische Behandlung des Alkoholentzugssyndroms: Fokus Delirium Tremens

  2022cites this paper
• Increased amisulpride serum concentration in a patient treated with concomitant pregabalin and trazodone: a case report

  2022cites this paper
• Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study

  2022cites this paper
• A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D2/3/5-HT7 inhibitor

  2022cites this paper
• Management of Psychiatric Disorders in Patients with Hepatic and Gastrointestinal Diseases

  2022cites this paper
• Effects of dopamine D2/3 and opioid receptor antagonism on the trade-off between model-based and model-free behaviour in healthy volunteers

  2022cites this paper
• The negative impact of vitamin D on antipsychotic drug exposure may counteract its potential benefits in schizophrenia

  2022cites this paper
• Going the extra mile? The influence of Amisulpride on effort-based decisions.

  2022cites this paper
• DDDT_A_327506 3903..3913

  2021cites this paper
• Influence of cytochrome P450 2D6 polymorphism on hippocampal white matter and treatment response in schizophrenia

  2021cites this paper
• Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level

  2021cites this paper
• Opioid antagonism reduces wanting by strengthening frontostriatal connectivity

  2021cites this paper
• Impaired Learning From Negative Feedback in Stimulant Use Disorder: Dopaminergic Modulation

  2021cites this paper
• Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta‐analysis

  2021cites this paper
• Opioid antagonism modulates wanting-related frontostriatal connectivity

  2021cites this paper
• No effect of a dopaminergic modulation fMRI task by amisulpride and L-DOPA on reward anticipation in healthy volunteers

  2020influential citation
• Amisulpride: tackling postoperative nausea and vomiting not a nightmare any more

  2020cites this paper
• An overview of intravenous amisulpride as a new therapeutic option for the prophylaxis and treatment of postoperative nausea and vomiting

  2020cites this paper
• Striatal Volume Increase After Six Weeks of Selective Dopamine D2/3 Receptor Blockade in First-Episode, Antipsychotic-Naïve Schizophrenia Patients

  2020cites this paper
• A systematic review and combined meta-analysis of concentration of oral Amisulpride.

  2020cites this paper
• Dopaminergic and opioidergic regulation during anticipation and consumption of social and nonsocial rewards

  2020cites this paper
• Genetic basis of schizophrenia: Basic hypothesis pathways and gene functions

  2020cites this paper
• Cholinergic and dopaminergic effects on prediction error and uncertainty responses during sensory associative learning

  2020cites this paper
• P.467 Safety, pharmacokinetics, and pharmacodynamics of LB-102, a selective D2 / 5-HT7 antagonist, in healthy volunteers

  2020cites this paper
• Machine learning identifies large-scale reward-related activity modulated by dopaminergic enhancement in major depression

  2019cites this paper
• Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses

  2019cites this paper
• Metabolism and Excretion of Intravenous, Radio-Labeled Amisulpride in Healthy, Adult Volunteers Clinical Pharmacology: Advances and Applications

  2019cites this paper
• An EEG investigation of pain processing in Parkinson's disease

  2019cites this paper
• Amisulpride and l‐DOPA modulate subcortical brain nuclei connectivity in resting‐state pharmacologic magnetic resonance imaging

  2019influential citation
• P.101 Building a translational bridge from animals to man for clinical candidate lb-102, a next-generation benzamide antipsychotic

  2019cites this paper
• Metabolism and Excretion of Intravenous, Radio-Labeled Amisulpride in Healthy, Adult Volunteers

  2019cites this paper
• Amisulpride

  2019cites this paper
• Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7

  2019cites this paper
• Antidepressant-like Effects of Amisulpride , Ketamine , and Their Enantiomers on Differential-Reinforcement-of-Low-Rate ( DRL ) Operant Responding in Male C 57 / BL / 6 Mice

  2019cites this paper
• Depressionen und Lebererkrankungen: Die Rolle von Mikrobiom und Inflammation

  2019cites this paper
• Dopamine manipulations drive changes in information sampling in healthy volunteers

  2019cites this paper
• Categorical and dimensional perspectives on depression in elderly primary care patients – Results of the AgeMooDe study

  2018cites this paper
• Clinical Pharmacokinetics of Atypical Antipsychotics: An Update

  2018influential citation
• Ventricular Arrhythmia during Tracheal Intubation and Extubation under General Anesthesia Possibly Induced by Amisulpride: A Case Report

  2018cites this paper
• Differential Noradrenergic Modulation of Monetary Reward and Visual Erotic Stimulus Processing

  2018cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2018cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2017cites this paper
• Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder

  2017cites this paper
• Respondents’ report of a clinician-diagnosed depression in health surveys: comparison with DSM-IV mental disorders in the general adult population in Germany

  2017cites this paper
• Dopamine Receptor-Specific Contributions to the Computation of Value

  2017cites this paper
• Antidepressant-like Effects of Amisulpride, Ketamine, and Their Enantiomers on Differential-Reinforcement-of-Low-Rate (DRL) Operant Responding in Male C57/BL/6 Mice

  2017cites this paper
• A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease.

  2017cites this paper
• Discriminative stimulus properties of the atypical antipsychotic amisulpride: comparison to its isomers and to other benzamide derivatives, antipsychotic, antidepressant, and antianxiety drugs in C57BL/6 mice

  2017cites this paper
• Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers
.

  2017cites this paper
• Spatiotemporal Suicide Risk in Germany: A Longitudinal Study 2007–11

  2017cites this paper
• The dopaminergic reward system underpins gender differences in social preferences

  2017cites this paper
• Dopamine Modulates the Functional Organization of the Orbitofrontal Cortex

  2017cites this paper
• Altersdepression

  2016cites this paper
• Genetic Variability in Organic Cation Transporters: Pathophysiological Manifestations and Consequences for Drug Pharmacokinetics and Efficacy

  2016cites this paper
• Occurrence and fate of amisulpride, sulpiride, and lamotrigine in municipal wastewater treatment plants with biological treatment and ozonation.

  2016cites this paper
• Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions

  2016cites this paper
• A Liquid Chromatography-Tandem Mass Spectrometry Method for Quantifying Amisulpride in Human Plasma and Breast Milk, Applied to Measuring Drug Transfer to a Fully Breast-Fed Neonate

  2016cites this paper
• Organic Cation Transporters

  2016cites this paper
• Dopamine D2/3- and μ-opioid receptor antagonists reduce cue-induced responding and reward impulsivity in humans

  2016cites this paper
• A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer’s disease

  2016influential citation
• Dopamine regulates stimulus generalization in the human hippocampus

  2016cites this paper
• An update of safety of clinically used atypical antipsychotics

  2016cites this paper
• Role of Amisulpride Augmentation in Treatment Resistant Major Depressive Disorder: An Open Label Study from North India

  2015cites this paper
• Dopamine D2-Receptor Blockade Enhances Decoding of Prefrontal Signals in Humans

  2015cites this paper
• A systematic microdialysis study of dopamine transmission in the accumbens shell/core and prefrontal cortex after acute antipsychotics

  2015cites this paper
• COMPARATIVE EVALUATION OF AMISULPRIDE AND ESCITALOPRAM ON SHEEHAN’S DISABILITY SCALE AMONG DEPRESSION PATIENTS IN A TERTIARY CARE TEACHING HOSPITAL IN NEPAL

  2015cites this paper
• The role of membrane transporters in the pharmacokinetics of psychotropic drugs: in vitro studies with special focus on organic cation transporters

  2015cites this paper
• Comparative evaluation of amisulpride and escitalopram on Hamilton Depression Rating Scale among depression patients in a tertiary care teaching hospital in Nepal

  2015cites this paper
• Comparative evaluation of amisulpride and escitalopram on Hamilton anxiety rating scale among depression patients in a tertiary care teaching hospital in Nepal

  2015cites this paper
• Development and evaluation of orodispersible sustained release formulation of amisulpride–γ-cyclodextrin inclusion complex

  2014cites this paper
• Prandial effect on the systemic exposure of amisulpride

  2014cites this paper
• Johann Christian August Heinroth on sleep deprivation as a therapeutic option for depressive disorders.

  2014cites this paper
• Characterising the neuropsychological profile of psychotic symptoms in Alzheimer's disease and imaging D2/3 receptor occupancy during treatment

  2014cites this paper
• Characterization of the discriminative stimulus properties of the atypical antipsychotic amisulpride in C57BL/6 mice

  2014influential citation
• Effects of Methamphetamine Administration on Information Gathering during Probabilistic Reasoning in Healthy Humans

  2014cites this paper
• Prandial effect on the systemic exposure of amisulpride

  2014cites this paper
• The Poorly Membrane Permeable Antipsychotic Drugs Amisulpride and Sulpiride Are Substrates of the Organic Cation Transporters from the SLC22 Family

  2014cites this paper
• ATYPICAL ANTIPSYCHOTICS: THE FIRST LINE TREATMENT FOR SCHIZOPHRENIA & PSYCHIATRIC DISORDERS

  2014cites this paper